TCRLAS v2.0 · WORKING DRAFT

Healthcare products & services. Independent evidence.

Assess the five healthcare H1–H5 dimensions independently. Category, intended use, claims and jurisdiction shape the requirements. CVA and maturity remain separate.

Private by design: this browser-only draft is held in memory. Refreshing, leaving this page or closing it loses unsaved work. Export your JSON for safekeeping and import it to continue. No automatic storage, accounts, database or submission. Do not enter patient-identifiable information or confidential business details. JSON exports are unencrypted.

Assessment scope

Classification review is required before restricted activity. No category or permission is inferred automatically.

Independent maturity record

Milestone: NE — not assessed.

CVA and HSE never assign maturity. Export this record, open the milestone tool, and import it there to review maturity. Import its exported record here to continue. All profiles and evidence remain in the complete JSON.

Open independent milestone assessment →

Healthcare evidence assessment (HSE)

Scores are ordinal evidence anchors, not probabilities. NE is unassessed. A zero needs an adverse evidence rationale. HSE N/A requires a documented applicability reason, reviewer and date; it is never converted into a score.

H1 — Regulatory and legal pathway
Inspect all H1 evidence anchors (0–6)
  1. 0: No credible lawful pathway for proposed activity, or known prohibitive legal issue.
  2. 1: Possible product/service category and governing authorities hypothesized.
  3. 2: Preliminary intended use, jurisdiction, classification and required permissions identified.
  4. 3: Documented category-specific compliance plan, qualified owners and evidence requirements.
  5. 4: Key regulatory assumptions supported by qualified review/interactions; required preparations underway.
  6. 5: Applicable requirements for the specific proposed activity substantially verified and fulfilled or controlled, with documented gaps.
  7. 6: Applicable permissions, quality/legal obligations and continuing compliance demonstrated for ongoing defined operations.
H1 evidence, confidence and rationale
H2 — Clinical / service effectiveness and safety evidence
Inspect all H2 evidence anchors (0–6)
  1. 0: No credible evidence for essential claims, or reliable evidence contradicts essential claims.
  2. 1: Health benefit or service outcome hypothesized.
  3. 2: Relevant scientific rationale, baseline performance and evidence plan drafted.
  4. 3: Credible measurement framework with appropriate preliminary analytical/clinical/service evidence.
  5. 4: Independent or relevant-environment evidence supports intended claims and safety for the defined stage.
  6. 5: Strong externally reviewed evidence and adverse-event/service-safety controls support proposed scope.
  7. 6: Robust repeatable clinical/service performance and continuing monitoring appropriate to claims demonstrated.
H2 evidence, confidence and rationale
H3 — Payer, purchaser and access
Inspect all H3 evidence anchors (0–6)
  1. 0: No viable purchaser, payment route or access path identified.
  2. 1: Potential payer, consumer, employer, provider or public purchaser posited.
  3. 2: Coverage, cash-pay, contracting and/or procurement options preliminarily researched.
  4. 3: Credible buyer and payment route documented with price, adoption barriers and access assumptions.
  5. 4: External customer, purchaser or payer feedback supports meaningful payment and adoption possibility.
  6. 5: Payment contracts or strongly supported ability/willingness to pay and practical market access demonstrated.
  7. 6: Repeatable payment and equitable, operationally sustainable market access demonstrated.
H3 evidence, confidence and rationale
H4 — Commercial delivery and channels
Inspect all H4 evidence anchors (0–6)
  1. 0: No credible route to intended customers/patients/providers.
  2. 1: Potential clinical, direct-to-consumer, employer, public or distribution pathway identified.
  3. 2: Candidate delivery, referral, procurement, support and distribution entities identified.
  4. 3: Working channel plan with buyer journey, fulfillment, data flows and support responsibilities.
  5. 4: Credible commitments or pilots from delivery/channel participants; service logistics mapped.
  6. 5: Verified functioning customer access and delivery with appropriate support and responsible parties.
  7. 6: Repeatable geographically/operationally relevant service or product delivery at scale.
H4 evidence, confidence and rationale
H5 — Healthcare execution system
Inspect all H5 evidence anchors (0–6)
  1. 0: Indispensable qualified clinical, quality, operational or contracting capability absent without solution.
  2. 1: Candidate qualified parties and organizational structure hypothesized.
  3. 2: Initial accountable roles for clinical/regulatory/quality/delivery identified.
  4. 3: Documented execution matrix, partner plan, agreements needed, funding and governance for next milestone.
  5. 4: Qualified parties, essential agreements and resources demonstrably committed for next milestone.
  6. 5: Execution network delivers safely, with relevant qualified systems, contingencies and documented oversight.
  7. 6: Repeatable resilient multi-party operation and required continuing healthcare oversight demonstrated.
H5 evidence, confidence and rationale

Critical blocker register

Record which activity a blocker affects. A restriction on launch does not by itself prohibit lawful preparatory research.

Commercialization Decision (CDA)

A named human reviewer records a bounded next-action decision. ADVANCE does not authorize launch.

Read the decision guide →

Unassessed decision: no authorization recorded.

Commercial Launch Decision

Separate named human review for a defined offering, scope and jurisdiction. GO is never produced by scores or checklist completion. CONDITIONAL refers only to activities already permitted.

Read the decision guide →

Applicable launch requirements

Scope being reviewed

Jurisdiction: not specified
Intended use: not specified
Claims: not specified

Qualified reviewers determine each requirement’s applicability for this exact scope. Changing scope clears previous requirement reviews.

These prompts are a working framework, not an exhaustive legal checklist. Review each against intended use, claims and jurisdiction with qualified people. Unreviewed or unresolved mandatory requirements prevent recording GO/CONDITIONAL.

Offering, intended use, claims, users, jurisdiction and launch scope — unreviewed
Offering, intended use, claims, users, jurisdiction and launch scope evidence
Applicable legal permissions and qualified review — unreviewed
Applicable legal permissions and qualified review evidence
Evidence supports claims and intended benefits — unreviewed
Evidence supports claims and intended benefits evidence
Delivery, accountable owners, continuity, support and incident controls — unreviewed
Delivery, accountable owners, continuity, support and incident controls evidence
Buyer/payment route, pricing, costs and available capital — unreviewed
Buyer/payment route, pricing, costs and available capital evidence
Named decision authority and documented review — unreviewed
Named decision authority and documented review evidence
Classification review before any restricted activity — unreviewed
Classification review before any restricted activity evidence
Health data privacy/security, consent and appropriate safeguards — unreviewed
Health data privacy/security, consent and appropriate safeguards evidence
Payer, purchaser or cash-pay access route; no assumption of reimbursement — unreviewed
Payer, purchaser or cash-pay access route; no assumption of reimbursement evidence

Unassessed decision: no authorization recorded.